The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic review☆.

[1]  O. Bednova,et al.  Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors? , 2020, International journal of molecular sciences.

[2]  Y. Lotan,et al.  Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. , 2020, Urologic oncology.

[3]  C. Lallas,et al.  MP24-17 SURGICAL COMPLICATIONS ASSOCIATED WITH PRE-OPERATIVE IMMUNOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER , 2020 .

[4]  Daniel J. Shapiro,et al.  PD39-08 PREOPERATIVE CHECKPOINT INHIBITORS ARE NOT ASSOCIATED WITH INCREASED SURGICAL COMPLICATIONS COMPARED TO PREOPERATIVE TYROSINE KINASE INHIBITORS OR UPFRONT CYTOREDUCTIVE NEPHRECTOMY , 2020 .

[5]  P. Verhagen,et al.  Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery. , 2020, Urologic oncology.

[6]  T. Naiki,et al.  Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab , 2020, International Cancer Conference Journal.

[7]  F. Montorsi,et al.  Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. , 2020, European urology.

[8]  K. Bensalah,et al.  Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? , 2020, European urology.

[9]  P. Cohen,et al.  Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma. , 2019, ANZ journal of surgery.

[10]  R. Figlin,et al.  The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) , 2019, Journal of Immunotherapy for Cancer.

[11]  A. Ravaud,et al.  Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial , 2019, Nature Medicine.

[12]  J. Brugarolas,et al.  Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. , 2019, Urologic oncology.

[13]  P. Sharma,et al.  A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). , 2019, Journal of Clinical Oncology.

[14]  S. Eggener,et al.  Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy , 2019, Journal of Immunotherapy for Cancer.

[15]  B. Rini,et al.  Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC). , 2019, Journal of Clinical Oncology.

[16]  W. Horninger,et al.  Prognostic Value of Testing PD‐L1 Expression After Radical Cystectomy in High‐risk Patients , 2018, Clinical genitourinary cancer.

[17]  T. Powles,et al.  SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer , 2018, World Journal of Urology.

[18]  T. Sugai,et al.  Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma , 2018, International journal of urology : official journal of the Japanese Urological Association.

[19]  K. Kabashima,et al.  Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..

[20]  J. Brugarolas,et al.  What is the role of nephrectomy following complete response to checkpoint inhibitors? , 2018, Urology case reports.

[21]  R. Montironi,et al.  Immune checkpoint inhibitors for metastatic bladder cancer , 2017 .

[22]  David Moher,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement , 2018, JAMA.

[23]  U. Maggiore,et al.  The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients. , 2016, Advances in chronic kidney disease.